Abstract:Invasion of infectious agents through mucosal surfaces can be prevented by use of the common mucosal immune system (CMIS), which interconnects inductive tissues, including Peyer's patches (PPs) and nasopharyngeal-associated lymphoreticular tissue (NALT), and effector tissues of the intestinal and respiratory tracts. In order for the CMIS to induce maximal protective mucosal immunity, co-administration of mucosal adjuvant has been shown to be essential. When vaccine antigen is administered together with mucosal adjuvant, antigen-specific T-helper (Th) 1 and Th2 cells, cytotoxic T lymphocytes (CTLs) and IgA B cell responses are effectively induced by oral or nasal routes via the CMIS. In the early stages of induction of mucosal immune response, the uptake of orally or nasally administered antigens is achieved through a unique set of antigen-sampling cells, M cells located in follicle-associated epithelium (FAE) of inductive sites. After successful uptake, the antigens are immediately processed and presented by the underlying dendritic cells (DCs). Elucidation of the molecular/cellular characteristics of M cells and mucosal DCs will greatly facilitate the design of a new generation of effective mucosal adjuvants and of a vaccine delivery vehicle that maximises the use of the CMIS. Our recent efforts at mucosal vaccine development have focused on nasal administration of vaccine antigen together with nontoxic mutant-based or cytokine-/chemokine-based adjuvant for the induction of the protective immunity. To this end, a chimeric form of a nontoxic adjuvant combining the merits of mutant cholera toxin A subunit (mCT-A) and heat labile toxin B subunit (LT-B) was created as the second generation of detoxified toxin-based mucosal adjuvant. When a vaccine antigen was coexpressed together with an immune stimulatory/delivery molecule in crop seed, this edible vaccine is not only effective but also extremely practical in that it can be produced in huge quantities and preserved and shipped over long distances at room temperature without altering the quality of the vaccine. Because such qualities would greatly facilitate global vaccination, this new generation edible vaccines with a built-in adjuvant and/or M cell-targeted edible vaccine promises to be a powerful weapon for combating infectious diseases and bioterrorism.

Mucosal adjuvants

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA

New generation of mucosal adjuvants for the induction of protective immunity

Mucosal Immunization With Helicobacter, Cpg Dna, And Cholera Toxin Is Protective

Adjuvant synergy: The effects of nasal coadministration of adjuvants

Recent Advances in Mucosal Adjuvant

Progress in Mucosal Immune Adjuvants

The mucosal immune system of the upper respiratory tract and recent progress in mucosal vaccines

Cytokines As Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (igg) and Iga Antibodies in Serum and Mucosal Secretions after Nasal Immunization

Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo

Mucosal Adjuvants for Influenza Virus-Like Particle Vaccine.

Mucosal Vaccine Development Based on Liposome Technology

Induction of Mucosal Immunity Through Systemic Immunization: Phantom or Reality?

Alpha-galactosylceramide is an Effective Mucosal Adjuvant for Repeated Intranasal or Oral Delivery of HIV Peptide Antigens

mRNA Technology and Mucosal Immunization

Α-Galcer is an Effective Mucosal Adjuvant for Repeated Nasal or Oral Delivery of HIV Peptide Antigens (39.54)

[Mucosal immunity and vaccines against viral infections]

Mucosal Vaccines for Moraxella Catarrhalis

Cholera toxin and cholera B subunit as oral—mucosal adjuvant and antigen vector systems

Induction of protective immune responses at respiratory mucosal sites

Mucoadhesive Vaccine Delivery Systems for the Oral Mucosa